Researchers from Icahn School of Medicine at Mount Sinai was recently awarded a U54 grant ($3.9 million over the first two years as a part of a five-year research proposal) to establish a NCI/SeroNet Center for Serological Excellence at Mount Sinai with a focus on lung cancer.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the Ohio State College of Pharmacy have been awarded a five-year, $7 million competitive Program Project grant renewal from NCI.
The Walther Cancer Foundation plans to invest $11 million to advance collaborative cancer research at Indiana University and Purdue University by supporting scientists through bioinformatics.
John Glaspy was named the inaugural Simms/Mann Family Foundation Endowed Chair in Integrative Oncology at David Geffen School of Medicine at University of California, Los Angeles.
The Sidney Kimmel Cancer Center–Jefferson Health and Thomas Jefferson University has said its cancer research programs will be clustered into four key areas: Cancer Risk and Control; Molecular Oncology Regulation and Approaches; Translational and Cellular Oncology; and Immune Cell Regulation and Targeting.
The global coronavirus pandemic has torn the veil that dimmed the nation's awareness of the breadth and depth of health disparities, including cancer health disparities.
NCI plans to mark the 50th anniversary of the National Cancer Act of 1971 with an effort to build a coalition of support for cancer research, including raising the payline to 15% by 2025.
Over the next two years, as president of the Association of American Cancer Institutes, Karen Knudsen will challenge her colleagues at North America's premier cancer centers to focus on reducing cancer disparities.
The Reagan-Udall Foundation for the FDA, with input from experts at FDA, has introduced an Expanded Access eRequest app to streamline expanded access for individual patients in non-emergency settings.
FDA has accepted the Biologics License Application for idecabtagene vicleucel (ide-cel; bb2121) as Priority Review.
